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Leukemia inhibitory factor (LIF) and oncostatin M (OSM) induce
DNA synthesis in Swiss 3T3 cells through common signaling mecha-
nism(s), whereas other related cytokines such as interleukin-6 and cil-
iary neurotrophic factor do not cause this response. Induction ofDNA
replication by LIF or prostaglandin F2 (PGF2) occurs, in part,
through different signaling events. LIF and OSM specifically trigger
STAT1cytoplasmic tonuclear translocation,whereasPGF2 fails todo
so. However, LIF and PGF2 can trigger increases in ERK1/2 activity,
which are required for their mitogenic responses because U0126, a
MEK1/2 inhibitor, prevents both ERK1/2 activation and induction of
DNA synthesis by LIF or PGF2 treatment. PGF2 induces cyclin D
expressionand full phosphorylationof retinoblastomaprotein. Incon-
trast, LIF fails to promote increases in cyclin DmRNA/protein levels;
consequently, LIF induces DNA synthesis without promoting full
phosphorylation of retinoblastoma protein (Rb). However, both LIF
and PGF2 increase cyclin E expression. Furthermore, LIF mitogenic
action does not involve protein kinase C (PKC) activation, because a
PKC inhibitor does not block this effect. In contrast, PKC activity is
required for PGF2 mitogenic action.More importantly, the synergis-
ticeffectbetweenLIFandPGF2 topromoteSphaseentry is independ-
ent of PKC activation. These results show fundamental differences
betweenLIF-andPGF2-dependentmechanism(s) that inducecellular
entry intoSphase.These findingsarecritical inunderstandinghowLIF
and other related cytokine-regulated events participate in normal cell
cycle control and may also provide clues to unravel crucial processes
underlying cancerous cell division.
Leukemia inhibitory factor (LIF)5 belongs to a closely related group of
cytokines, which includes oncostatin M (OSM), ciliary neurotrophic
factor (CNTF), interleukin 6 (IL-6), and cardiotrophin-1 (1–4).
Depending on the cell type, LIF promotes cellular proliferation or dif-
ferentiation, e.g. embryonic stem cell growth (5, 6), mammalian embryo
implantation (2, 4), neuronal differentiation (7, 8), enhancing survival of
peripheral neurons (7) and oligodendrocytes (10), promoting bone for-
mation (11), and myoblast proliferation (12–14). LIF is also implicated
in a variety of pathophysiological processes (15–19). Cellular responses
to LIF as well as to other cytokines are initiated via heterodimerization
of twomembers of the cytokine receptor family (8, 20, 21). The resultant
signal transduction process involves activation of cytoplasmic Janus
kinases (8, 20, 21), which in turn promote tyrosine phosphorylation of
the signal transducers and activators of transcription (STATs), thereby
enabling them to translocate to the nucleus and initiate gene transcrip-
tion of LIF-responsive genes (22). LIF can also trigger alternative signal-
ing processes to those causing STAT activation (23). These include
activation of the mitogen-activated protein kinase (MAPK) cascade,
including the mitogen-activated protein kinase kinase (MAPKK or
MEK), the MAPK isoenzymes (ERK1 and ERK2), and activation of S6
protein kinase (8).
We have shown previously that Swiss 3T3 cells are equally responsive
to both sets of growth factors; LIF and PGF2 are thus equally effective at
inducing DNA synthesis (25). The generality of the difference in signal-
ing events triggered by both cytokines and growth factors in different
cell systems is well established; cytokines trigger activation of Janus
kinases that promote phosphorylation of STATs (8, 20–22), and growth
factors triggered mitogen-induced Raf/MEK/ERK signaling pathway
leading to overexpression of cyclin D (26–29, 42–45). However,
because these mitogens have been tested in different cellular systems, it
is unknown whether this difference is a function of the cell type or is a
fundamental difference in the delivery of the transducing signal per se.
Thus, we have systematically studied LIF-, OSM-, and PGF2-depend-
ent mechanisms of control of S phase entry into the Swiss 3T3 cell
system.Wehave shownpreviously that LIF-triggered signals differ from
those triggered by classical mitogens, such as PGF2, bombesin, or epi-
dermal growth factor (30–32) in Swiss 3T3 cells. LIF and OSM trigger
initiation of DNA synthesis without the requirement formevalonic acid
synthesis because inhibition of the hydroxymethylglutaryl-CoA reduc-
tase by lovostatin does not block LIF- orOSM-inducedDNAreplication
and cell multiplication (32). Indeed, because LIF triggers cellular entry
into the S phase via a PKC-independent signaling mechanism, it
becomes relevant to investigate which activation cascade (MAPK
and/or JAK/STAT) is involved in the onset of DNA replication and cell
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division. Here we show that LIF and OSM stimulate the initiation of
DNA synthesis and cell division through a common signaling mecha-
nism that involves MEK/ERK activation as well as STAT1 cytoplasmic-
nuclear translocation. Signals triggered by LIF and OSM are independ-
ent of PKC activation. On the other hand, PGF2 triggers activation of
MEK/ERK but fails to activate STAT1 cytoplasmic-nuclear transloca-
tion. The different signaling pathways involved in the mitogenic
response to cytokines and growth factors cause a major effect on G1
cyclin expression. PGF2, as the majority of classical growth factors,
induces the expression of cyclin Ds as an important step in the G0 to S
phase transition.However, LIF-stimulated S phase entry occurswithout
changes in the levels of cyclin Ds but with increases in cyclin E expres-
sion. These findings are relevant for understanding how LIF, in partic-
ular, and cytokines, in general, regulate the events involved in control-
ling the normal cell cycle. These studies are also important for
unraveling critical signaling events capable of underlying unrestricted
cancerous cell division.
MATERIALS AND METHODS
Chemicals—Themajority of thematerials was purchased fromSigma
unless otherwise indicated. The mouse recombinant carrier-free LIF,
OSM, CNTF, and IL-6 were purchased from R&D (Minneapolis, MN).
PGF2 was the generous gift from Dr. M. Torkelston, Upjohn (Kalama-
zoo,MI), and theGF109203Xwas kindly provided byGlaxoSmithKline.
U0126 was purchased from Calbiochem. [methyl-3H]Thymidine was
purchased from PerkinElmer Life Sciences.
Cell Culture—Swissmouse 3T3 cells were grown inDulbecco’s mod-
ified Eagle’s medium containing 100 units of penicillin/ml, 100 g of
streptomycin/ml, and 10% (v/v) fetal calf serum. Subconfluent cultures
were grown in 100-mmdishes at 37 °C equilibrated with 10% (v/v) CO2.
Initiation of DNA Synthesis Assay—Cells were seeded at 1.5  105 in
35-mm dishes in 2 ml of Dulbecco’s modified Eagle’s medium supple-
mentedwith lowmolecularweight nutrients (DEMS), 1% (v/v) newborn
calf serum, and 6% (v/v) fetal calf serum. After 3 days of incubation, the
medium was changed to a similar fresh medium, and the cells were
further incubated for 3–4 days to allow them to become confluent and
quiescent. Cytokines and growth factors were directly added to the con-
ditioned medium. Cells were then labeled with [methyl-3H]thymidine
for 28 h before being processed for autoradiography. The percentage of
cells that initiated DNA synthesis at a given time was determined as
described previously (25, 33).
Cell Number—Cells were plated at 1.5 105 in 60-mmdishes in 5ml
of medium, for the determination of the initiation of DNA synthesis.
When cells became quiescent, but were still subconfluent, the corre-
sponding cytokines or prostaglandins were added to the culture
medium, and the cell number was determined 60 h later. Cells were
detached from the dish using 5mM EDTA, 0.05% (v/v) trypsin for 5min
at 37 °C and counted in a Coulter counter (34).
MAPK Assay—MAPK activity assays were performed on subconflu-
ent Swiss 3T3 cells by immunoprecipitation of total endogenous ERK.
Cells were maintained for 16 h in serum-free medium and then treated
with agents as indicated in the figure legends, washedwith cold PBS, and
lysed at 4 °C in a buffer containing 25 mM HEPES (pH 7.5), 0.3 M NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 1% (v/v) Triton
X-100, 0.5% (v/v) sodium deoxycholate, 0.1% (v/v) SDS, 20 mM -glyc-
erophosphate, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl flu-
oride, 20 g/ml aprotinin, and 20 g/ml leupeptin. ERK was immuno-
precipitated from the cleared lysates by incubation with the specific
antibody (sc-154 from Santa Cruz Biotechnology) for 1 h at 4 °C. Immu-
nocomplexes were recovered with the aid of Gamma-bind-Sepharose
Beads (Amersham Biosciences) and washed three times with PBS con-
taining 1% (v/v) Nonidet P-40 and 2 mM Na3VO4, once with 100 mM
Tris-HCl (pH 7.5), 0.5 M LiCl, and once in kinase reaction buffer (12.5
mM MOPS (pH 7.5), 12.5 mM 3-glycerophosphate, 7.5 mM MgCl2, 0.5
mM EGTA, 0.5 mM sodium fluoride, 0.5 mM sodium vanadate). The
ERK-2 activity present in the immunoprecipitates was determined by
resuspension in 30 l of kinase reaction buffer containing 10 Ci of
[-32P]ATP per reaction and 20 M of unlabeled ATP, using 20 g of
myelin basic protein (MBP) as a substrate, as described previously (35).
After 20 min at 30 °C, reactions were terminated by addition of 10 l of
5Laemmli buffer. Sampleswere heated 5min at 95 °C and analyzed by
SDS-gel electrophoresis on 12% (w/v) polyacrylamide gels. Autoradiog-
raphy was performed with the aid of an intensifying screen. Parallel
immunoprecipitates were processed forWestern blot analysis using the
same antiserum as described previously (35).
Indirect Immunofluorescence—It was performed on sparse quiescent
Swiss 3T3 cells, adhering to coverslips. After stimulation, cells were
fixed and permeabilized with 3.7% (v/v) formaldehyde in PBS plus
0.2%(v/v) saponin for 10 min at room temperature. Cells were then
blocked for 30min with 10% (v/v) heat-inactivated goat serum and then
incubated overnight at 4 °C with 20 g/ml of the primary antibody
diluted in PBS, 0.1%(v/v) saponin. The primaries antibodies used were
as follows: STAT1 antibody (G16920), STAT3 antibody (S21320), and
STAT5 antibody (S21520) from BD Transduction Laboratories. The
coverslips were washed three times with PBS and further incubated for
1 h with fluorescein isothiocyanate-conjugated goat anti-mouse IgGs
(Sigma) diluted 1/50 in PBS. Finally the cells were washed three times
with PBS and mounted with 1,4-diazabicyclo[2.2.3]octane solution
(Sigma). Images were obtained on a BX-60Olympus fluorescent micro-
scope. The percentage of cells in which STAT1 translocated to the
nucleus upon LIF or LIF plus Na3VO4 treatment was determined in
three independent experiments by counting the number of nuclear and
non-nuclear stained cells in at least five fields, each containing an aver-
age of at least 150 cells, at different time points.
SDS-PAGE and Immunoblotting—Proteins were separated on 12%
(w/v) SDS-polyacrylamide gels and transferred to nitrocellulose filters.
Transfers were blocked overnight at 4 °C with 5% (v/v) nonfat milk in
TBS, 0.1% (v/v) Tween 20 and then incubated for 1 h at room temper-
ature in the primary antibody diluted in 5% (v/v) nonfat milk in TBS,
0.1%(v/v) Tween 20. The primary antibodies usedwere as follows: phos-
phospecific p42/p44MAPK antibody (sc-7383; diluted 1/1000), p42/
p44MAPK antibody (sc-154; 1/1000), cyclinD1 antibody (sc-450; 1/1000),
cyclin D2 antibody (sc-593; 1/1000), cyclin D3 antibody (sc-6283;
1/1000), cyclin E antibody (sc-481; 1/1000), CDK4 antibody (sc-260;
1/1000), andCDK6 antibody (sc-177; 1/1000) from Santa Cruz Biotech-
nology; cyclin A antibody (C4710) from Sigma. The transfers were
rinsed with TBS, 0.1% (v/v) Tween 20 and incubated for 1 h at room
temperature in horseradish peroxidase-conjugated pig anti-rabbit or
rabbit anti-mouse serum (Dako) diluted 1/5000 in 5% (v/v) nonfat milk
inTBS, 0.1% (v/v) Tween 20. The immunoblotswere developedwith the
ECL detection reagent (Amersham Biosciences).
Northern Blot—Cells were plated at 3.0  105 in 100-mm dishes
similar to the assay for DNA synthesis. Under these conditions, cultures
became confluent and quiescent at a saturating density of 3  106 cells.
In experiments where the levels of cyclin D1 mRNA were determined
after various times of addition of growth factors, total RNA was pre-
pared from cells by extracting them with Trizol reagent. Samples (15
g) were subjected to 1% (v/v) MOPS/formaldehyde agarose-gel elec-
trophoresis and blotted onto nylon membranes. The membranes were
hybridized with 32P-labeled cDNA probes for cyclin D1 and 18 S RNA
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with a Promega kit, washed, and exposed to x-ray film (36). For cyclinD1
the 1.3-kbp EcoRI fragment of pcBZ04.1 was used. Cyclin D1 and 18 S
RNA cDNA probes were generously provided by Drs. C. D. Sherr (St.
Jude’s Hospital, Memphis, TN) and A. R. Kornblihtt (Physiology and
Molecular Biology Laboratory, School of Sciences, University of Buenos
Aires, Argentina), respectively.
RESULTS
LIF and OSM Induce DNA Synthesis through Common Signaling
Mechanism(s)—To investigate whether LIF-triggered signals that
induce cell proliferation can be shared by other related cytokines, such
as OSM, CNTF, and IL-6, we studied their ability to induce cellular
entry into S phase in resting Swiss 3T3 cells. Both LIF and OSM, added
at either subsaturating (10 ng/ml) or saturating (100 ng/ml) concentra-
tions, stimulated the initiation of DNA synthesis inducing 8 and 29% of
cells to enter into S phase after 28 h, respectively (Fig. 1), as shown
previously (32). When both LIF and OSM were added together, they
caused only an additive effect on the percentage of cells that entered into
S phase at any concentration tested (Fig. 1). In contrast, treatment of
Swiss 3T3 cells with IL-6 or CNTF did not induce cellular entry into the
S phase (Fig. 1). Taken together, these results suggest that LIF andOSM
may share common signaling pathway(s) to induce the entry into S
phase.
To examine whether LIF- or OSM-triggered signals differ from those
elicited by PGF2, we analyzed the ability of PGF2 to enhance LIF- or
OSM-dependent induction to S phase entry. PGF2 treatment stimu-
lated the initiation of DNA synthesis in Swiss 3T3 cells by inducing 7
and 25% of cells to enter into S phase after 28 h (Fig. 1), similarly to the
effect observed with LIF or OSM. Most interestingly, when PGF2 and
LIF were added together at either subsaturating or saturating concen-
trations, the stimulatory effect of LIF or PGF2 in inducing DNA syn-
thesis was potentiated by raising the fraction of cells that entered into S
phase to 57 and 67%, respectively (Fig. 1). Similarly, the stimulatory
effect of OSM was potentiated by PGF2 (Fig. 1). These results suggest
that LIF or OSM in combination with PGF2 exhibited a synergistic
effect by increasing the percentage of cells entering S phase. Further-
more, we hypothesized that the synergistic effect observed between LIF
orOSMwith PGF2 to induce bothDNA synthesis and cell divisionmay
be due, at least in part, to the activation of different signaling pathways
promoted by LIF and OSM with respect to those activated by PGF2.
LIF and PGF2 Activate MAPK Signaling Pathway with a Different
Kinetic Pattern—To ascertain whether the mitogenic effect of LIF and
PGF2 on Swiss 3T3 cells involved differential activation of a well char-
acterized MAPK cascade (37), we examined the capacity of LIF and
PGF2 to activate ERK. Treatment of Swiss 3T3 cells with LIF or PGF2
resulted in different kinetic patterns of ERK activation. LIF promoted a
maximum increase of ERK activity only at 12 min (Fig. 2B), whereas
PGF2 caused a maximum increase in ERK activity within 4 min (Fig.
2A). There was no change in the levels of p44/p42 MAPK throughout
this period (Fig. 2, A and B).
Because both LIF and PGF2 promote the activation of ERK1/2, we
investigated whether LIF- or PGF2-triggered activation of ERK is
required for their mitogenic effect. Treatment of cells with U0126, a
widely usedMEK inhibitor (38), for 1 h before addition of growth factors
caused a significant and progressive reduction in either LIF- or PGF2-
induced ERK phosphorylation without affecting the overall levels of this
protein (Fig. 3A). Indeed, U0126 at 10 M inhibited ERK activity by 90%
in both PGF2- and LIF-stimulated cells (Fig. 3B).Moreover, addition of
U0126 from 0.5 to 5M to cells prior to LIF or PGF2 treatment resulted
in a progressive inhibition of DNA replication (Fig. 3C). However,
although U0126 at 1 M effectively blocked PGF2-stimulated DNA
synthesis by 90%, a higher concentration of 3 M was required to cause
a similar effect with LIF-stimulated cells. In contrast, U0126 did not
FIGURE 1. Induction of DNA synthesis by LIF and OSM. To measure cellular entry into
S phase, quiescent Swiss 3T3 cells were treated with each cytokine and growth factor at
saturating or subsaturating concentrations and then labeled with [methyl-3H]thymidine
for 28 h. Radioactive label incorporation was analyzed by autoradiography (see under
“Materials and Methods”). Additions were as follows: LIF (10 ng/ml), OSM (10 ng/ml),
CNTF (10 ng/ml), IL-6 (10 ng/ml), PGF2 (30 ng/ml) at subsaturating concentrations, and
LIF (100 ng/ml), OSM (100 ng/ml), CNTF (100 ng/ml), IL-6 (100 ng/ml), and PGF2 (300
ng/ml) at saturating concentrations. Results represent the mean  S.E. of four independ-
ent experiments.
FIGURE 2. LIF or PGF2 triggered ERK activation
with a different kinetic pattern. Quiescent Swiss
3T3 cells were treated with PGF2 (300 ng/ml) (A)
or LIF (100 ng/ml) (B). Cells were lysed at time inter-
vals from 0 to 60 min, and kinase activity was
measured as indicated under “Materials and Meth-
ods.” Data represent the mean  S.E. of three inde-
pendent experiments, expressed as fold increase
in kinase activity with respect to untreated cells.
Upper panel, densitometric analysis expressed as
fold increase in kinase activity with respect to
untreated cells; middle panel, 32P-labeled MBP as
product of the kinases reaction for one represent-
ative experiment; lower panel, equal amounts of
ERK protein were immunoprecipitated as shown
by Western blot analysis of the immunoprecipi-
tated samples using anti-ERK antibodies.
LIF-triggered Signals and Cell Cycle Control
6138 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281 • NUMBER 10 • MARCH 10, 2006
affect DNA synthesis stimulated by fetal bovine serum (FBS). These
results showed that ERK activation is required for both LIF- and PGF2-
triggered cellular entry into S phase, although with a different kinetic
pattern.
Role of JAK/STAT Signaling Pathway in LIF/PGF2-induced DNA
Synthesis—To investigate whether LIF, OSM, and PGF2 exert a differ-
ential stimulation of the JAK/STAT pathway, we examined their ability
to cause cytoplasmic to nuclear translocation of the different STATs by
indirect immunofluorescence upon treatment of subconfluent resting
Swiss 3T3 cells. In control, nonstimulated cells, STAT1 was mainly
diffusely distributed within the cytoplasm (Fig. 4A). LIF andOSM treat-
ment promoted nuclear translocation of STAT1 as demonstrated by the
nuclear immunostaining of STAT1 (Fig. 4, panels A, B, and D, respec-
tively). In contrast, PGF2 did not trigger STAT1 nuclear localization
(Fig. 4A, panel C). Results similar to those found by immunofluores-
cence were obtained when the subcellular localization of STAT1 was
determined by analyzing cytoplasmic and nuclear fractions of LIF-stim-
ulated cells by Western blotting (data not shown). Furthermore, LIF,
OSM, and PGF2 could not promote translocation of STAT3 or STAT5
to the nucleus in the 3T3 cells (not shown). As positive controls, anti-
STAT3 and STAT5 antibodies were able to detect STAT3 and STAT5
cytoplasmic to nuclear translocation in 3T3 L1 pre-adipocytes stimu-
lated by different cytokines, growth factors, and hormones (data not
shown) (39). No translocation was observed with either IL-6 or CNTF,
which are not mitogenic for Swiss 3T3 cells (Fig. 4B).
FIGURE 3. ERK activation is required for LIF- or PGF2-dependent DNA synthesis. A,
cells were treated with vehicle (lane C), LIF (100 ng/ml), or PGF2 (300 ng/ml) for 12 and 4
min, respectively, in the absence or presence of U0126. Cells were lysed, and equal
amounts of protein were analyzed by Western blot using a specific phospho-ERK1/2
antibody (upper panel) or a specific ERK2 antibody (lower panel). The results are repre-
sentative of three independent experiments. B, cells were left untreated or treated with
LIF (100 ng/ml) or PGF2 (300 ng/ml) for 12 and 4 min, respectively, in the absence or
presence of U0126 (10 M). Endogenous ERK2 protein was immunoprecipitated from the
cell extracts and kinase activity assayed using MBP as substrate. Data represent the
mean  S.E. of three independent experiments expressed as fold increase in kinase
activity with respect to untreated cells. C, to measure the effect of ERK inhibition on LIF-
or PGF2-stimulated DNA synthesis, quiescent Swiss 3T3 fibroblasts were treated for 28 h
with LIF (100 ng/ml), PGF2 (300 ng/ml), and FBS (10%v/v) in the absence or presence of
the indicated concentrations of U0126 and then labeled with [methyl-3H]thymidine.
U0126 was added 1 h prior to the growth factors. The percentage of cells that entered
into S phase was determined by autoradiography, as described under “Materials and
Methods.” The results are presented as the percentage of labeled nuclei with respect to
the growth factor alone and are representative of four independent experiments.
FIGURE 4. LIF, but not PGF2, promotes nuclear translocation of STAT1. A, subcon-
fluent Swiss 3T3 cells were treated with vehicle (A), LIF (100 ng/ml) (B), OSM (ng/ml) (D),
or PGF2 (300 ng/ml) (C) for 15 min. Cells were fixed, and STAT1 localization was visual-
ized by indirect immunofluorescence with an anti-STAT1 monoclonal antibody as
described under “Materials and Methods.” Insets in panels show a higher magnification
of a cell for better visualization. Percentage of cells with STAT1 nuclear staining is as
follows: control, 10  4%; LIF, 89  5%; OSM, 85  7%; and PGF2, 15  6%. B, kinetic
pattern of STAT1 translocation was determined as follows. Swiss 3T3 cells were stimu-
lated with LIF in the absence or presence of Na3VO4 (30 M). This inhibitor was added 1 h
prior to cell treatment. Cells were fixed, and the STAT1 localization was visualized by
indirect immunofluorescence as described under “Materials and Methods.” The percent-
age of STAT1-immunostained nuclei was determined at different times after cytokine
addition. At least 750 cells were counted per time point. The results represent the
means  S.E. of three independent experiments.
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To ascertain whether regulation of tyrosine phosphatases is impli-
cated in LIF-dependent nuclear localization of STAT1, Swiss 3T3 cells
were incubated in the presence or absence of Na3VO4, a general inhib-
itor of tyrosine phosphatases (40, 41), prior to and during cytokine treat-
ment. LIF-promoted cytoplasmic-nuclear translocation of STAT1
occurred as rapidly as 2 min after addition of LIF, and its nuclear local-
ization attained a plateau at 10–15min and declined to the basal level by
60 min (Fig. 4B). In the presence of Na3VO4, LIF also promoted the
rapid translocation of STAT1 to the nucleus. However, in the presence
ofNa3VO4, STAT1 remains in the nucleus after 60min of LIF treatment
(Fig. 4B). This observation is consistent with findings that showed that a
phosphatase inhibitor could prolong the activation of STAT1 and thus
its nuclear retention (42). Indeed, Na3VO4 alsomarkedly enhanced LIF-
induced cellular entry into S phase, raising the percentage of cells under-
going DNA synthesis over 2.5-fold (Fig. 5). Na3VO4 also enhanced
OSM- and PGF2-dependent cellular entry into the S phase (Fig. 5).
These experiments indicated that LIF-dependent activation of STAT1
and initiation of DNA replication might both involve tyrosine kinase
activation. In contrast, the PGF2-dependent mitogenic effect appears
not to require STATs activation.
Effect of LIF and PGF2 on G1 Cyclin Expression and pRb Phosphoryl-
ation—To determine whether differences between LIF/OSM and
PGF2 signaling pathways have major consequences on expression of
key G1 cyclins and their effector kinases involved in executing the G1/S
transition, the expression of cyclins was assessed at different times upon
treatment of quiescent 3T3 cells with LIF or PGF2. Fig. 6 shows that
PGF2 raised cyclin D1 protein levels within 9 h, reaching a plateau after
12–15 h, and these levels remained relatively high for up to 21 h (Fig.
6A). PGF2 also raised cyclin D2 protein levels at later times (within
15–21 h of treatment) but failed to increase cyclin D3 protein levels (Fig.
6A). In contrast, LIF as well as OSM failed to increase cyclin D1 protein
and mRNA levels (Fig. 6, A and B), as well as failing to raise cyclin D2 or
cyclin D3 protein levels (Fig. 6A). IL-6 and CNTF were also unable to
induce cyclin D1mRNA levels (Fig. 6B). The levels of the corresponding
partner CDK4/6 kinases (43) did not show any increase upon LIF or
PGF2 treatments (Fig. 6A). However, addition of LIF induced an
increase in cyclin E and cyclin A protein levels after 14 and 28 h to levels
comparable with that induced by 10% FBS, at least for cyclin E (Fig. 6C).
PGF2 increases cyclin E and A protein levels similar to those for LIF
(data not shown).
Cyclin D-CDK complexes were shown to phosphorylate the retino-
blastoma tumor suppressor protein (pRb), leading to inactivation of pRb
(44). It is well documented that inactivation of pRb results in release or
derepression of the E2F transcription factors and drives cell entry into
the S phase (44). To examine whether differences in cyclin D expression
mediated by LIF and PGF2 result in differences in pRb phosphoryla-
tion, quiescent Swiss 3T3 cells were induced to enter S phase, and phos-
phorylation of pRb was assessed by immunoblotting. As shown in Fig.
FIGURE 5. Inhibition of tyrosine phosphatases enhances LIF induction of DNA syn-
thesis. To analyze the effect of tyrosine phosphatase inhibition on LIF stimulation of
DNA synthesis, quiescent Swiss 3T3 cells were treated for 28 h with LIF (100 ng/ml) or
OSM (100 ng/ml) in the absence or presence of 30 M Na3VO4 and then labeled with
[methyl-3H]thymidine. C, control. The Na3VO4 was added 1 h before the cytokine treat-
ment. The percentage of cells that entered into S phase was determined by autoradiog-
raphy, as described under “Materials and Methods.” Results represent the means  S.E.
of three independent experiments.
FIGURE 6. The mitogenic effect of LIF is independent of cyclin D expression. A,
Swiss3T3 cells were treated with vehicle or saturating concentrations of LIF (100 ng/ml)
or PGF2 (300 ng/ml) for different periods of time. Cell extracts were prepared, and equal
amounts of protein were analyzed by immunoblotting using specific antibodies for
cyclin D1, cyclin D2, cyclin D3, CDK4, and CDK6 (see “Materials and Methods”). Data are
representative of three independent experiments. B, cyclin D1 mRNA levels were deter-
mined at various times after cytokine or PGF2 treatment. Swiss 3T3 cells were treated
with vehicle or saturating concentrations of LIF (100 ng/ml), OSM (100 ng/ml), CNTF (100
ng/ml), IL-6 (100 ng/ml), or PGF2 (300 ng/ml). After 8 –10 h, total RNA was extracted from
cells; Northern blot was performed as described under “Materials and Methods.” North-
ern blot densitometric analysis was standardized to 18 S RNA. Similar results were
obtained in three independent experiments. C, Swiss 3T3 cells were treated with vehicle,
LIF, or FBS for various times. Cell extracts were prepared, analyzed by SDS-PAGE, and
immunoblotted using specific antibodies against cyclin D1, cyclin E, and cyclin A. Results
are representative of three independent experiments. D, extracts from cells treated with
vehicle (lane C), PGF2, LIF, or FBS for the indicated periods of time were separated by
SDS-PAGE and subjected to immunoblot analysis for pRb. Arrows indicate pRb with dif-
ferent levels of phosphorylation.
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6D, LIF did not promote full phosphorylation of pRb (lane 4 versus lane
1). In contrast, PGF2 induced hyperphosphorylation of pRb (Fig. 6D,
lanes 2 and 3 versus lane 1), consistent with the induction of expression
of cyclins Ds. Phosphorylation of pRB induced by PGF2 is comparable
with the level of pRb phosphorylation induced by FBS (Fig. 6D, lane 5)
upon cell entry into S phase. In summary, LIF induces neither expres-
sion of cyclin Ds nor hyperphosphorylation of pRb, whereas PGF2
promotes both the increase in the expression of cyclinDs and the hyper-
phosphorylation of pRb to exert its mitogenic effect. Taken together,
these results provide further evidence that LIF and PGF2 may act
through different signaling and molecular events to control the initia-
tion of cellular entry into S phase.
The Synergistic Effect of LIF and PGF2 to Induce S Phase Entry Is
Independent of PKC Activation—We have shown previously that LIF
and PGF2 differ markedly in the requirement for PKC in stimulating
DNA synthesis (25). LIF triggers cellular entry into S phase via a PKC-
independent signaling mechanism, whereas PGF2 requires the activa-
tion of the PKC signaling pathway (25). Therefore, we examined
whether PGF2-dependent activation of PKC plays a role in the syner-
gistic effect observed between LIF and PGF2 in the induction of DNA
synthesis in Swiss 3T3 cells. We tested the effect of increasing concen-
trations of GF109203X, a specific inhibitor of PKC, on the ability of LIF
and PGF2 alone or in combination to trigger DNA replication. As
shown in Fig. 7A, GF109203Xprogressively inhibited PGF2-dependent
DNA replication but completely failed to block LIF-dependent DNA
replication. These results are consistent with our previous findings
obtained with 12-O-tetradecanoylphorbol-13-acetate indicating that
LIF and PGF2 differed markedly in the requirement for PKC in stimu-
lating DNA synthesis (25). Most interestingly, GF109203X did not pre-
vent the synergistic effect between PGF2 and LIF in increasing the
percentage of cells that entered into S phase (Fig. 7B). These results
suggest that the synergistic effect of LIF and PGF2 to promote S phase
entry is independent of PKC activation.
DISCUSSION
It has been shown previously that Swiss 3T3 cells are equally respon-
sive to both sets of growth factors; LIF and PGF2 are thus equally
effective at inducing DNA synthesis (25). The generality of the differ-
ence in signaling events triggered by both cytokines and growth factors
in different cell systems is well established; cytokines trigger activation
of Janus kinases that promote phosphorylation of STATs (8, 23–25),
and growth factors trigger the mitogen-induced Raf/MEK/ERK signal-
ing pathway leading to overexpression of cyclin D (26–29, 42–45).
However, because these mitogens have been tested in different cellular
systems, it is unknown whether this difference is a function of the cell
type or is a fundamental difference in the delivery of the transducing
signal per se. In this study we show that LIF-triggered signaling mecha-
nism(s) for inducing cellular entry into S phase are shared only by OSM
and not by PGF2 in the same quiescent Swiss mouse 3T3 cell system.
Their differences are not due to subpopulations of 3T3 cells that are
primarily responsive to LIF/OSM or to PGF2, because repeated sub-
cloning of 3T3 cells and addition of LIF/OSM or PGF2 yield the same
percentages of cells stimulated to synthesize DNA in the given time
period.6 Treatment of Swiss 3T3 cells with LIF or OSM together with
PGF2mutually potentiated their ability to induce cellular DNA synthe-
sis, whereas co-treatment of cells with LIF and OSM rendered no fur-
ther increase. Experimentally cellular DNA synthesis ismeasured by the
fraction of cells with [3H]DNA in their nuclei after 28 h. A longer expo-
sure of cells to [3H]thymidine with one mitogen increases this fraction,
eventually reaching almost 100%of the cell population (22, 25, 27, 28, 33,
34). The synergy observed between LIF and PGF2 merely increases the
rate of cellular entry into S phase but not the absolute fraction of cells
that are responding. These observations suggest that LIF andOSM trig-
ger common signaling pathways that may differ from those activated by
PGF2 for the induction of DNA synthesis. The importance of the study
therefore lies in the uncovering of the biochemical differences in the
signal transduction pathways of these two groups of mitogens in the
same cell system.
ERK1/2 are components of the well known MAPK signaling cascade
activated by mitogens and are thus involved in controlling cell prolifer-
ation (37). Here we show that both LIF or PGF2 by themselves can
promote ERK activation. However, LIF and PGF2 differ in their timing
ofMAPK activation. Although PGF2 induced amaximumat 4min, LIF
did so only after 12min after addition, a result that suggests that LIF and
PGF2 cause ERK activation via two separate upstream signaling events.
U0126, a highly specific MEK inhibitor, blocked both LIF- and PGF2-
triggeredMAPK activation and theirmitogenic responses, strongly sug-
gesting that MAPK activation is required for the initiation of both LIF
and PGF2-dependent DNA synthesis. However, how LIF increases
ERK activity and the consequent stimulation of DNA synthesis in these
cells is still unknown. MAPK activation is more complex than a simple
linear pathway. For example, LIF-triggered ERK1/2 activity in 3T3-L1
adipocytes can occur via both Raf-1-dependent and -independent pro-
6 P. Rudland and L. Jiménez de Asúa, unpublished results.
FIGURE 7. The synergistic effect between LIF
and PGF2 to induce S phase entry is independ-
ent of PKC activation. A, quiescent Swiss 3T3 cells
were treated for 28 h with LIF or PGF2 in the
absence or presence of GF109203X added 1 h
prior to the addition of growth factors and then
labeled with [methyl-3H]thymidine. The percent-
age of cells that entered into S phase was deter-
mined by autoradiography, as described under
“Materials and Methods.” B, quiescent Swiss 3T3
cells were treated for 28 h with vehicle, LIF, PGF2,
or LIF and PGF2 in the absence or presence of
GF109203X (10 M) added 1 h prior to addition of
growth factors. The percentage of cells that
entered into S phase was determined by autora-
diography. Results represent the mean  S.E. of
four independent experiments.
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cesses (22). In addition, it has been shown that an increase in phosphati-
dylinositol 3-kinase activity may be involved in ERK activation (45) and
that phosphatidylinositol 3-kinase may play a role in prolonging ERK
activity (46). Moreover, cytokines such as interferon  or OSM can
activate Raf-1 in a Ras-independent manner via increased activity of
JAK1 or Tyk2 (47). These findings and our present results support the
notion that multiple, temporally distinct pathways can converge on
MAPK and that these pathways can be utilized differentially by various
stimuli and cell types.
Cyclin D1 expression is generally regulated by a mitogen-induced
Raf/MEK/ERK signaling pathway (26–29). Indeed, the duration of an
ERK signal appears to determine whether cells will induce cyclin D1
expression. Mitogens that only produce a transient ERK activation fail
to induce cyclinD1, whereas growth factors that induce a sustained ERK
activation cause continuous maintenance of cyclin D1 expression (48,
49). Thus, the critical determinant in the induction of cyclin D1 is the
duration, rather than the intensity, of the ERK signal. Our studies show
that LIF-stimulatedDNA synthesis requires an intactMEK/ERK signal-
ing cascade. However, LIF-stimulated ERK activation is likely not to be
linked to the increase in cyclin D1 expression. In contrast, PGF2-stim-
ulated ERK activation may be directly involved with increasing the
expression of cyclin D and ultimately with its mitogenic response. How
LIF promotes S phase entry in an ERK-dependentmanner and howERK
activation does not result in an increase in cyclin D1 expression have yet
to be elucidated. The results presented here suggest that the different
kinetics of MAPK activation may result in a different pattern of G1
cyclin expression, although alternative explanations based on ERK1/2-
independent activation of the cyclin D1 promoter by PGF2 and not by
LIF may be possible.
JAK/STAT signal cascades are known to be involved in responses to
cytokines. Our immunofluorescence studies reveal that LIF and OSM
trigger a similar pattern of STAT1 cytoplasmic to nuclear translocations
after 2 min, attaining amaximum at 10–15min and declining at 60min
to the basal level, whereas CNTF, IL-6, and PGF2 were without effect.
Our experiments to understand the role of LIF induction of DNA syn-
thesis indicated that the effect of LIF is mediated via tyrosine kinase
because Na3VO4 potentiates LIF’s stimulation of DNA synthesis. Fur-
thermore, this result is correlated with the prolonged localization of
STAT1 in the nucleus. However, it will be important to elucidate
whether STAT1 cytoplasmic-nuclear translocation in conjunction or
not with MAPK activation is required for LIF stimulation of DNA
synthesis.
LIF is overproduced and secreted by several cancer cells (50, 51) and
thus may act as an autocrine stimulator. Moreover, it is known that
during oncogenesis different STAT proteins are continuously activated
in a variety of cancer cells types (52, 53), and if inhibited the resultant
cancer cells grow much more slowly (52, 53, 60, 61). The fact that cyto-
kines stimulate DNA replication through different signaling events may
result in carcinomas rapidly eluding the control of growth factor signals,
and therefore any therapy targeted to the early signaling events trig-
gered by growth factors may become rapidly ineffective. Thus the elu-
cidation of themolecular mechanism of cytokine action is an important
step in dissecting deranged regulatory events leading to malignant
transformation and as a second parallel target for mounting a therapeu-
tic blockade aimed at preventing cancer cell proliferation.
Although LIF fails to increase any cyclin D1 levels, LIF-triggered S
phase entry is accompanied by prior increases in cyclin E and cyclin A
levels, which are a downstream event(s) to the increase of cyclin D1
expression (54). Thus, LIF-triggered entry into S phase differs markedly
from that triggered by classic mitogens, such as PGF2, bombesin, and
other growth factors, which must increase the levels of cyclin Ds to
induce S phase entry (36, 55, 56). Whether the low basal levels of cyclin
D/CDK4 are sufficient to trigger the next step, phosphorylation of Rb
(57), or whether this first stage of Rb phosphorylation is bypassed is
unknown at present. Moreover, different findings reveal that cyclin
E/CDK2 can induce cellular entry into S phase in the absence of cyclin
D/CDK4 activation (56, 58) and that c-Myc andCdc25A can participate
in the activation of the cyclin E-CDK2 complex (59–61). A recent
report demonstrates that proliferation of mouse embryonic fibroblasts
proceeds relatively normally in the absence of the D-cyclins (62). Kozar
et al. (62) shows that mouse embryonic fibroblasts from cyclin D1/
D2/D3/ mice critically depend on CDK2, suggesting that cyclin
D-CDK4/6 and cyclin E-CDK2 complexes may perform overlapping
functions in “cyclin D-independent” systems. It is established that the
initial phosphorylation of the pRb by cyclin D-CDK complexes is
required to allow full phosphorylation of the pRb by the cyclin E- and
cyclinA-associated kinases (9, 63).However, Kozar et al. (62) shows that
phosphorylation of pRb on cyclin D-specific sites is not required for
further phosphorylation and that cyclin E- and cyclin A-driven phos-
phorylation is sufficient to allow the expression of E2Fs target genes
during cell cycle re-entry. Our study shows that LIF promotes expres-
sion of cyclin E andA but not cyclinDs, as shown in Fig. 6. Furthermore,
full phosphorylation of pRb does not take place as cells re-enter the cell
cycle. Therefore, our future goal will be to elucidate the role of cyclin
E/CDK2 in regulating LIF induction of DNA replication in a cyclin
D-independent manner.
In summary, our present work demonstrates that LIF and PGF2
trigger different signaling and molecular events prior to cellular entry
into S phase in the same cell system. The importance of this work estab-
lishes that stem cell factors like LIF can bypass the normal growth fac-
tor-inducedRaf/MEK/ERK signaling pathway to cyclinD and activation
of CDK4/6, the key event that normally allows progress through the
Restriction Point R and commitment to enter the cell cycle (54). LIF and,
by implication, stem cell growth factors in general then trigger cellular
entry into S phase by partial phosphorylation of Rb through increases in
cyclin E and activation of CDK2. Thus the enhancing effect of PGF2 on
the induction of cellular entry into S phase mediated by LIF is probably
because of the ability of the former mitogen to phosphorylate Rb com-
pletely and thereby further reduce its inhibitory activity for the E2F
transcription factor required for G1 to S phase transition (54). Presum-
ably, this synergy is mediated by interactions between those signals
generated from the PGF2 receptor that are different from those of LIF,
in particular the very early rise in ERK activation and the activation of
STAT1. By understanding the molecular mechanisms by which LIF in
particular and cytokines in general control normal cell cycle constitutes
the basis to unravel the critical cytokine-related signaling events under-
lying unrestricted cancerous cell division, as well as providing possible
therapeutic targets to blockade this second signal transduction pathway
in the event that it is necessary to inhibit both growth factor and cyto-
kine signaling pathways to prevent cancer cell growth.
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